<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110486</url>
  </required_header>
  <id_info>
    <org_study_id>M10-944</org_study_id>
    <nct_id>NCT01110486</nct_id>
  </id_info>
  <brief_title>ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, pharmacokinetics and maximum tolerated&#xD;
      dose of ABT-348 as monotherapy and when given in combination with carboplatin or docetaxel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to determine the safety, pharmacokinetics and maximum&#xD;
      tolerated dose of ABT-348 as monotherapy and when given in combination with carboplatin or&#xD;
      docetaxel. The secondary purpose of this study is to evaluate safety at the recommended Phase&#xD;
      2 dose and evaluate preliminary efficacy data regarding objective response rate time to&#xD;
      progression, duration of overall response, and ECOG performance status of ABT-348 as&#xD;
      monotherapy and when given in combination with carboplatin or docetaxel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety profile (Adverse events by toxicity grade and relationship to study drug, serious adverse events, adverse events leading to discontinuation and relevant clinical laboratory abnormalities) of ABT-348 as monotherapy or in combination</measure>
    <time_frame>At each treatment visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study the pharmacokinetic of ABT-348</measure>
    <time_frame>At study visits</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose limiting toxicity determination</measure>
    <time_frame>At each treatment visit until dose-limiting toxicities observed</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety at the recommended Phase 2 dose (RPTD) and schedule of ABT-348 as monotherapy, when in combination with carboplatin or in combination with docetaxel.</measure>
    <time_frame>At RPTD treatment visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary efficacy data regarding objective response rate (ORR), time to progression (TTP), duration of overall response, and ECOG performance status of ABT-348 as monotherapy, when in combination with carboplatin or docetaxel.</measure>
    <time_frame>At each treatment visit</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Monotherapy, once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination with carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination with docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy, twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Monotherapy, once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-348</intervention_name>
    <description>An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.</description>
    <arm_group_label>Monotherapy, once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-348 and carboplatin</intervention_name>
    <description>An oral dose of ABT-348 will begin in Cycle 2on Day 1 and Day 8; and an IV dose of carboplatin (AUC 5.0) on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Combination with carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-348 and docetaxel</intervention_name>
    <description>ABT-348 dosing will begin in Cycle 2. An oral dose of ABT-348 on Day 1 and Day 8; and an IV dose of docetaxel (75 mg/m2) on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Combination with docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-348</intervention_name>
    <description>An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle</description>
    <arm_group_label>Monotherapy, twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-348</intervention_name>
    <description>An IV administration of ABT-348 two hour infusion on Day 1, Day 8 and Day 15 of each 28 day cycle.</description>
    <arm_group_label>IV Monotherapy, once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological confirmation of locally advanced or metastatic solid tumor.&#xD;
&#xD;
               -  That is either refractory after standard of care therapy for the disease for&#xD;
                  which standard of care therapy is not reliably effective or does not exists, or&#xD;
&#xD;
               -  For which carboplatin has been determined to be an appropriate therapy, per the&#xD;
                  investigator, or&#xD;
&#xD;
               -  For which docetaxel has been determined to be an appropriate therapy, per the&#xD;
                  investigator.&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group Status of 0-2&#xD;
&#xD;
          3. Serum creatinine value of ≤ 1.5 times the upper limit of normal (ULN) and either an&#xD;
             estimated creatinine clearance value as determined by the Cockcroft-Gault formula or&#xD;
             based on a 24 hour urine collection creatinine clearance value of ≥ 50 mL/min&#xD;
&#xD;
          4. Adequate liver function as demonstrated by serum bilirubin &lt; 2 x ULN and AST and ALT ≤&#xD;
             2.5 x ULN&#xD;
&#xD;
          5. Adequate bone marrow as demonstrated by absolute neutrophil count (ANC) ≥ 1,500/mm2&#xD;
             (1.5 x 109/L); Platelets ≥ 100,000/mm2 (100 x 109/L); Hemoglobin ≥ 9.0 g/dL (1.4&#xD;
             mmol/L)&#xD;
&#xD;
          6. QTc interval &lt; 500 msec&#xD;
&#xD;
          7. Left Ventricular Ejection Fraction &gt; 50%&#xD;
&#xD;
          8. Women of child-bearing potential and men must agree to use adequate contraception (one&#xD;
             of the following listed below) prior to the study entry, for the duration of study&#xD;
             participation and up to 3 months following completion of therapy.&#xD;
&#xD;
          9. Capable of understanding and complying with parameters as outlined in the protocol and&#xD;
             able to sign informed consent, approved by an Institutional Review Board (IRB) prior&#xD;
             to the initiation of any screening or study-specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has known active CNS involvement. The subject has untreated brain or meningeal&#xD;
             metastases.&#xD;
&#xD;
          2. Subject has received anti-cancer therapy within a period of 21 days or 5 half lives&#xD;
             (whichever is shorter) prior to Study Day 1&#xD;
&#xD;
          3. Subject has unresolved toxicities from prior anti-cancer therapy, grade 2 or higher&#xD;
             clinically significant toxicity (excluding alopecia)&#xD;
&#xD;
          4. Subject has had major surgery within 28 days prior to Study Day 1&#xD;
&#xD;
          5. Subject currently exhibits symptomatic or persistent, uncontrolled hypertension&#xD;
             defined as diastolic blood pressure &gt; 90 mmHg or systolic blood pressure &gt; 140 mmHg&#xD;
&#xD;
          6. Subject has proteinuria grade &gt; 1 7. Subject is receiving therapeutic anticoagulation&#xD;
             therapy. Low dose anti coagulation (e.g., low dose heparin or warfarin) for catheter&#xD;
             prophylaxis will be permitted.&#xD;
&#xD;
        8. Clinically significant uncontrolled condition(s) 9.Psychiatric illness/social situation&#xD;
        that would limit compliance with study requirements 10. Subject has a known infection with&#xD;
        HIV, Hepatitis B or Hepatitis C 11. Subject with poorly controlled diabetes mellitus 12.&#xD;
        Subject enrolled in Arm A, B, C and D is unable to swallow or absorb oral tablets normally&#xD;
        13. Any medical condition which in the opinion of the study investigator places the subject&#xD;
        at an unacceptably high risk for toxicities 14. Female subjects who are lactating or&#xD;
        pregnant 15. Subject enrolled in Arm E has hypersensitivity to drugs formulated with&#xD;
        polyethoxylated castor oli (Cremophor)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Gordon, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 26525</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 26524</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>March 26, 2010</study_first_submitted>
  <study_first_submitted_qc>April 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2010</study_first_posted>
  <last_update_submitted>November 4, 2013</last_update_submitted>
  <last_update_submitted_qc>November 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Ilorasertib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

